SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    K. Meijer, S. Rauchensteiner, E. Santagostino, H. Platokouki, R. E. G. Schutgens, M. Brunn, C. Tueckmantel, F. Valeri, P. C. Schinco, Continuous infusion of recombinant factor VIII formulated with sucrose in surgery: Non-interventional, observational study in patients with severe haemophilia A, Haemophilia, 2015, 21, 1
  2. 2
    C. L. Eckhardt, J. I. Loomans, A. S. Velzen, M. Peters, E. P. Mauser-Bunschoten, R. Schwaab, M. G. Mazzucconi, A. Tagliaferri, B. Siegmund, S. E. Reitter-Pfoertner, J. G. Bom, K. Fijnvandraat, Inhibitor development and mortality in non-severe hemophilia A, Journal of Thrombosis and Haemostasis, 2015, 13, 7
  3. You have free access to this content3
    D. Lillicrap, K. Fijnvandraat, E. Santagostino, Inhibitors – genetic and environmental factors, Haemophilia, 2014, 20,
  4. You have free access to this content4
    R. D. Paschal, S. L. Meeks, A. T. Neff, Development of factor VIII inhibitors in two patients with moderate haemophilia A, Haemophilia, 2013, 19, 1
  5. 5
    C. L. Eckhardt, A. S. van Velzen, M. Peters, J. Astermark, P. P. Brons, G. Castaman, M. H. Cnossen, N. Dors, C. Escuriola-Ettingshausen, K. Hamulyak, D. P. Hart, C. R. M. Hay, S. Haya, W. L. van Heerde, C. Hermans, M. Holmstrom, V. Jimenez-Yuste, R. D. Keenan, R. Klamroth, B. A. P. Laros-van Gorkom, F. W. G. Leebeek, R. Liesner, A. Makipernaa, C. Male, E. Mauser-Bunschoten, M. G. Mazzucconi, S. McRae, K. Meijer, M. Mitchell, M. Morfini, M. Nijziel, J. Oldenburg, K. Peerlinck, P. Petrini, H. Platokouki, S. E. Reitter-Pfoertner, E. Santagostino, P. Schinco, F. J. Smiers, B. Siegmund, A. Tagliaferri, T. T. Yee, P. W. Kamphuisen, J. G. van der Bom, K. Fijnvandraat, Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A, Blood, 2013, 122, 11, 1954

    CrossRef

  6. You have free access to this content6
    A. Srivastava, A. K. Brewer, E. P. Mauser-Bunschoten, N. S. Key, S. Kitchen, A. Llinas, C. A. Ludlam, J. N. Mahlangu, K. Mulder, M. C. Poon, A. Street, Guidelines for the management of hemophilia, Haemophilia, 2013, 19, 1
  7. 7
    Donna M. DiMichele, Inhibitors in childhood hemophilia A: Genetic and treatment-related risk factors for development and eradication, Pediatric Blood & Cancer, 2013, 60, S1
  8. 8
    D. Stephensen, E. C. Rodriguez-Merchan, Orthopaedic co-morbidities in the elderly haemophilia population: a review, Haemophilia, 2013, 19, 2
  9. 9
    Hartmut Pollmann, Robert Klamroth, Natascha Vidovic, Alexander Y. Kriukov, Joshua Epstein, Ingo Abraham, Gerald Spotts, Johannes Oldenburg, Prophylaxis and quality of life in patients with hemophilia A during routine treatment with ADVATE [antihemophilic factor (recombinant), plasma/albumin-free method] in Germany: a subgroup analysis of the ADVATE PASS post-approval, non-interventional study, Annals of Hematology, 2013, 92, 5, 689

    CrossRef

  10. 10
    C. HERMANS, J. ASTERMARK, P. DE MOERLOOSE, Exposure to factor VIII and prediction of inhibitor development: exposure days vs. danger days, or both?, Journal of Thrombosis and Haemostasis, 2012, 10, 10
  11. 11
    Donna M. DiMichele, Immune tolerance in haemophilia: the long journey to the fork in the road, British Journal of Haematology, 2012, 159, 2
  12. 12
    Corien L. Eckhardt, Evelien P. Mauser-Bunschoten, Marjolein Peters, Frank W. G. Leebeek, Felix J. M. van der Meer, Karin Fijnvandraat, Inhibitor incidence after intensive FVIII replacement for surgery in mild and moderate haemophilia A: a prospective national study in the Netherlands, British Journal of Haematology, 2012, 157, 6
  13. 13
    E. P. MAUSER-BUNSCHOTEN, I. E. M DEN UIJL, R. E. G SCHUTGENS, G. ROOSENDAAL, K. FISCHER, Risk of inhibitor development in mild haemophilia A increases with age, Haemophilia, 2012, 18, 2
  14. You have free access to this content14
    Barbara A. Konkle, The aging patient with hemophilia, American Journal of Hematology, 2012, 87, S1
  15. 15
    A. TAGLIAFERRI, C. DI PERNA, F. RICCARDI, C. PATTACINI, G. F. RIVOLTA, M. FRANCHINI, The natural history of mild haemophilia: a 30-year single centre experience, Haemophilia, 2012, 18, 2
  16. 16
    R. J. Summers, S. L. Meeks, J. F. Healey, H. C. Brown, E. T. Parker, C. L. Kempton, C. B. Doering, P. Lollar, Factor VIII A3 domain substitution N1922S results in hemophilia A due to domain-specific misfolding and hyposecretion of functional protein, Blood, 2011, 117, 11, 3190

    CrossRef

  17. You have free access to this content17
    D. M. DI MICHELE, Immune tolerance induction in haemophilia: evidence and the way forward, Journal of Thrombosis and Haemostasis, 2011, 9,
  18. 18
    C. L. ECKHARDT, J. G. van der BOM, M. VAN DER NAALD, M. PETERS, P. W. KAMPHUISEN, K. FIJNVANDRAAT, Surgery and inhibitor development in hemophilia A: a systematic review, Journal of Thrombosis and Haemostasis, 2011, 9, 10
  19. 19
    Treatment of haemophilia: building on strength in the third millennium, Haemophilia, 2011, 17,
  20. 20
    Angelika Batorova, Uri Martinowitz, Continuous Infusion of Coagulation Products in Hemophilia,
  21. 21
    Johanna G. van der Bom, Epidemiology of Inhibitors,
  22. 22
    Cindy Leissinger, Rebecca Kruse-Jarres, General Surgical Management of Patients with Hemophilia,
  23. 23
    Kathelijne Peerlinck, Marc Jacquemin, Inhibitors to Factor VIII: Mild and Moderate Hemophilia,